Articles related to NON-HODGKIN LYMPHOMA (NHL)
CAR T-Cell Therapy for Relapsed/Refractory Non-Hodgkin’s Lymphoma (NHL): A Comprehensive Review
CAR T-cell therapy has changed the treatment paradigm for relapsed/refractory aggressive B-cell NHL. The approach has seen strong response rates and durable remission in those whose disease has progressed despite multiple prior treatments. This review outlines current indications for CAR T-cell therapy, major toxicities, novel CARs under investigation, CARs for various hematologic malignancies, and future directions.
Oncology, Medical May 25th 2022
CAR T-Cell Therapy for Relapsed/Refractory Non-Hodgkin’s Lymphoma: A Comprehensive Review
This review of CAR T-cell therapy for NHL overviews topics such as use in 2nd line, novel CARs, mantle cell lymphoma application, indolent B-cell lymphomas, toxicities, application in older patients, and other relevant subjects.
Oncology, Medical May 18th 2022
Moderna COVID-19 Vaccine May Be More Effective in CLL Patients
In a single-center study of 240 patients with lymphoid malignancies — 181 with CLL, 21 with WM, and 38 with other non-Hodgkin lymphomas (NHLs) – patients with CLL were significantly more likely to have an antibody response to the Moderna vaccine compared to the Pfizer-BioNTech vaccine. This superior response was demonstrated in both treatment naïve and treated CLL populations in the study.
Oncology, Medical April 12th 2022
Tisagenlecleucel vs. SOC as 2L Therapy of Primary R/R Aggressive B-Cell NHL: Analysis of the Phase III Belinda Study
Adults with confirmed R/R aNHL within 12 months after first-line (1L) chemo-immunotherapy were eligible for the randomized Phase III study, which demonstrated that tisagenlecleucel (tisa-cel) as second-line (2L) treatment in R/R aNHL patients did not have a higher event-free survival (EFS) vs. the standard-of-care (SOC). Read this late-breaking abstract from the ASH Annual Meeting & Exhibition to discover the contributing factors leading to the results, as well as how insights from this study will inform use of cellular treatment in the 2L R/R aNHL setting and the design of future CAR-T trials.
Hematology December 7th 2021
Activity of mRNA COVID-19 Vaccines in Patients with Lymphoid Malignancies
Publication: Blood AdvancesStudy Design: Prospective study with unmatched health care workforce control group, receiving either Moderna or Pfizer COVID vaccination.Study Population: 23 patients with CLL (61%), lymphoma (39%) (including DLBCL), MCL (13%) and 4% with less common lymphomas.Outcome: Lymphoma patients had significantly lower anti-S IgG titers 28 days post-vaccination compared with controls. Related Article: Efficacy of the BNT162b2 mRNA COVID-19 Vaccine in Patients with B-Cell Non-Hodgkin Lymphoma
Allergy & Immunology August 31st 2021